论文部分内容阅读
目的：为了治疗血管性痴呆。方法：选择诊断为轻中度血管性痴呆患者60例，随机分为治疗组40例，对照组20例．治疗组用常规疗法加迪纳康片40mg，po，tid；对照组仅用常规疗法。采用MMSE，HDS和ADL于治疗前后（3个月）统计分值变化进行疗效评估。结果：治疗组显效率12．5％．有效率52．5％，对照组分别为5．0％和30．0％。治疗组MMSE，HDS．ADL积分增加值优于对照组（P均＜0．05），且未发现明显副作用及肝肾功能损害。结论：达纳康治疗血管性痴呆疗效肯定，副作用少。
Purpose: To treat vascular dementia. Methods: Sixty patients diagnosed as mild to moderate vascular dementia were randomly divided into treatment group (n = 40) and control group (n = 20). The treatment group with conventional therapy plus medina tablets 40mg, po, tid; control group only with conventional therapy. MMSE, HDS and ADL in the treatment before and after (3 months) statistical score changes for the efficacy evaluation. Results: The treatment group was 12.5% efficient. The effective rate was 52.5% in the control group and 5.0% and 30.0% respectively. Treatment group MMSE, HDS. The added value of ADL score was better than the control group (all P <0.05), and no obvious side effects and liver and kidney dysfunction were found. Conclusion: Danakang treatment of vascular dementia with certain side effects.